Focusing on Testosterone - 05/11/11
, Robert Dreicer b, c
Reprint requests: Judd Moul, M.D., Department of Urologic Surgery, Duke University Medical Center, Room 1573, Duke South DUMC 3707, Durham, NC 27710Résumé |
Since Huggins and Hodges first established testosterone as the principal androgenic hormone responsible for the growth of prostate cancer in 1941, lowering the circulating testosterone to surgical castration levels (<50 ng/dL) has been a fundamental strategy for prostate cancer therapy. Until the 1980s, surgical castration (bilateral orchiectomy) and medical castration using estrogen (diethylstilbestrol) were the primary methods of testosterone suppression. However, during the past 30 years, newer agents that lower serum testosterone even more effectively have been approved and the indications for use of these newer agents re-evaluated.
Le texte complet de cet article est disponible en PDF.Plan
| Financial Disclosure: J. W. Moul is a member of the Speaker's Bureau for Sanofi-Aventis, Astra-Zeneca, GSK, Ferring. R. Dreicer has received grant/research support from Millenium; and has worked as a consultant for Sanofi Aventis, Novartis, Astra Zeneca, GTX, EMD Serano, Boehringer Ingelheim, Centecor Ortho Biotech, and Millenium. |
Vol 78 - N° 5S
P. S476-S477 - novembre 2011 Retour au numéro
Article précédent
- New Data, New Paradigms for Treating Patients With Prostate Cancer: Introduction
- Judd W. Moul, Robert Dreicer
- Indications and Practice With Androgen Deprivation Therapy
- Judd W. Moul, Adam S. Kibel, Mack Roach, Robert Dreicer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?